Related references
Note: Only part of the references are listed.A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation
Joseph S. Bubalo et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2023)
Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience
Barbara Loteta et al.
SUPPORTIVE CARE IN CANCER (2022)
Predicting the presence and mechanism of busulfan drug-drug interactions in hematopoietic stem cell transplantation using pharmacokinetic interaction network-based molecular structure similarity and network pharmacology
Chenxia Hao et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study
Nicola Di Renzo et al.
BONE MARROW TRANSPLANTATION (2020)
Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life
Meinolf Karthaus et al.
FUTURE ONCOLOGY (2020)
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation
Vincenzo Apolito et al.
ANNALS OF HEMATOLOGY (2020)
Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey
Pascale Dielenseger et al.
SUPPORTIVE CARE IN CANCER (2019)
Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses
Rebecca Clark-Snow et al.
SUPPORTIVE CARE IN CANCER (2018)
Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy
Lee S. Schwartzberg et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2018)
Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey
Matti Aapro et al.
CANCER REPORTS (2018)
A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
L. Zhang et al.
ANNALS OF ONCOLOGY (2018)
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
G. Dranitsaris et al.
ANNALS OF ONCOLOGY (2017)
Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?
Terry L. Ng et al.
ONCOLOGIST (2015)
Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey
Cheryl Vidall et al.
SUPPORTIVE CARE IN CANCER (2015)
Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2,388 health care providers
Emily S. Van Laar et al.
SUPPORTIVE CARE IN CANCER (2015)
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
P. J. Hesketh et al.
ANNALS OF ONCOLOGY (2014)
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
R. J. Gralla et al.
ANNALS OF ONCOLOGY (2014)
A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
M. Aapro et al.
ANNALS OF ONCOLOGY (2014)
Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects
Marigo Stathis et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
In vitro and in vivo pharmacological characterization of the novel NK1 receptor selective antagonist Netupitant
Anna Rizzi et al.
PEPTIDES (2012)
Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life
P. Fernandez-Ortega et al.
SUPPORTIVE CARE IN CANCER (2012)
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation
S. A. Giralt et al.
ANNALS OF ONCOLOGY (2011)
Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT
M. Musso et al.
BONE MARROW TRANSPLANTATION (2010)
Share Paper
